Insilico Medicine develops new AI-generated FGFR2/3 inhibitor for tissue-agnostic solid tumors

What hap­pened to Pfiz­er? In 2022, the com­pa­ny made Big Phar­ma his­to­ry: break­ing $100 bil­lion in rev­enue, thanks to its Covid-19 block­busters. CEO Al­bert Bourla

The FDA is propos­ing to tight­en its reg­u­la­tions on com­pound­ing three cat­e­gories of drugs that the agency de­ter­mined are too dif­fi­cult to com­pound, ac­cord­ing to